Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Ixekizumab in Indian patients with mild to moderate psoriasis for 24 weeks follow up.: After baseline screening which included history,PASI,DLQ1 and
lab investigation,
Ixekizumab was ad
Sponsors
Department Of Dermatology Mahatma Gandhi Medical College aad Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age more than 18 years with chronic plaque psoriasis for at least 6 months 2. PASI more than or equalto 12 or BSA more than or equal to 10 percent or sPGA score more than or equal to 3 3. Intolerance to systemic therapy
Exclusion criteria
Exclusion criteria: 1. Pustular guttate, erythrodermic psoriasis 2. Previous biology therapy within 6 months 3. Pregnant or lactating women. 4. Active infection or immunocompromised state. 5. Significant hepatic or immunocompromised 6. Patients with hypersensitivity reactions like urticaria, anaphylaxis, and angioedema 7.Patient with inflammatory bowel disease 8. Known hypersensitivity to monoclonal antibodies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvment in PASI, DLQI,score and adverse event recording.Timepoint: Week1,2,4,12,24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. 1. Patient achieving PASI50 at week 2. 2.Patient achieving PASI75 at week 2 3.Patient achieving PASI90 at week 4. 4. Patient achieving PASI100 at week 8.Timepoint: Every 2 week followup for 12 weeks and then every 4 wwek follow up for next 12 week. Total duration 24 weeks | — |
Countries
India
Contacts
Public ContactDr.Pratibha Sharma
Mahatma Gandhi Medical College and Hospital, Jaipur,302022
Outcome results
None listed